Articles dans des revues avec comité de lecture (84)
1.
Francisse, S., Gkolfakis, P., Fernandez Y Viesca, M., Mans, L., Demols, A., Pezzullo, M., Loi, P., Navez, J., Closset, J., Bali, M. A., Van Wettere, M., D'Haene, N., Demetter, P., Verset, L., Bouchart, C., Lemmers, A., Devière, J., Delhaye, M., Van Laethem, J.-L., & Arvanitakis, M. (2023). The impact of a multidisciplinary team approach on the management of focal pancreatic lesions: a single tertiary center experience. Annals of Gastroenterology, 36(5), 580-587. doi:10.20524/aog.2023.08272.
Moeremans, M., Avni, F., D'Haene, N., Lam, N. M., Metens, T., & D'Hondt, A. (2023). Combined prenatal US and post-mortem fetal MRI: can they replace conventional autopsy for fetal body abnormalities? European radiology. doi:10.1007/s00330-023-09847-y3.
Demols, A., Rocq, L., Perez-Casanova Garcia, L., Charry, M., De Nève, N., Ramadhan, A. M., Van Campenhout, C., De Clercq, S., Maris, C., Closset, J., Lucidi, V., Salmon, I., & D'Haene, N. (2023). A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas. The oncologist, 28(7), e520-e525. doi:10.1093/oncolo/oyad0754.
Racu, M.-L., Bernardi, D., Chaouche, A., Zindy, E., Navez, J., Loi, P., Maris, C., Closset, J., Van Laethem, J.-L., Decaestecker, C., Salmon, I., & D'Haene, N. (2023). SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy. Cancers (Basel), 15(15). doi:10.3390/cancers151537655.
Lebrun, L., Absil, L., Remmelink, M., De Mendonça, R., D'Haene, N., Gaspard, N., Rusu, S., Racu, M.-L., Collin, A., Allard, J., Zindy, E., Schiavo, A. A., De Clercq, S., De Witte, O., Decaestecker, C., Lopes, M. B., & Salmon, I. (2023). SARS-Cov-2 infection and neuropathological findings: a report of 18 cases and review of the literature. Acta neuropathologica communications, 11(78). doi:10.1186/s40478-023-01566-16.
Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., Koopmansch, B., D'Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J.-L., & Bellahcène, A. (2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12(10), 1414. doi:10.3390/cells121014148.
Dufraing, K., Van Casteren, K., Breyne, J., D'Haene, N., Van Campenhout, C., Vander Borght, S., Zwaenepoel, K., Rouleau, E., Schuuring, E., von der Thüsen, J., & Dequeker, E. (2022). Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders. BMC cancer, 22(1), 736. doi:10.1186/s12885-022-09798-59.
Pasau, T., Wauters, E., Wauters, I., Duplaquet, F., Pirard, L., Stanciu-Pop, C., D'Haene, N., Dupont, M., Vander Borght, T., Rondelet, B., & Ocak, S. (2022). Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. Frontiers in oncology, 12, 985446. doi:10.3389/fonc.2022.98544610.
Racu, M.-L., Lebrun, L., Schiavo, A. A., Van Campenhout, C., De Clercq, S., Absil, L., Minguijon Perez, E., Maris, C., Decaestecker, C., Salmon, I., & D'Haene, N. (2022). The Role of SMAD4 Inactivation in Epithelial-Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link? Cancers (Basel), 14(4). doi:10.3390/cancers1404097311.
Verocq, C., Racu, M.-L., Bafort, D., Butorano, G., Perez-Casanova Garcia, L., Navez, J., Witterwulghe, M., Sheahan, K., Swan, N., Closset, J., Van Laethem, J.-L., Maris, C., & D'Haene, N. (2021). Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report. Diagnostic Pathology, 16(1). doi:10.1186/s13000-021-01178-012.
Rusu, S., Verocq, C., Trepant, A.-L., Maris, C., De Nève, N., Blanchard, O., Van Campenhout, C., De Clercq, S., Rorive, S., Cotoi, O. S., Decaestecker, C., Salmon, I., & D'Haene, N. (2021). Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma. Molecular and clinical oncology, 15(6), 270. doi:10.3892/mco.2021.2432